Increased approvals--myth or reality.
作者信息
Gingerich D A
机构信息
Stolle Research & Development Corp., Cincinnati, OH 45242.
出版信息
J Am Vet Med Assoc. 1993 May 15;202(10):1703-7;discussion 1713-7.
PMID:8514589
Abstract
摘要
相似文献
1
Increased approvals--myth or reality.
J Am Vet Med Assoc. 1993 May 15;202(10):1703-7;discussion 1713-7.
2
[Experiences with Lysodren treatment of Cushing's syndrome in dogs].
Tierarztl Prax. 1983;11(4):507-20.
3
[Experiences with Lysodren therapy of Cushing's syndrome in the dog (1)].
Tierarztl Prax. 1983;11(3):369-84.
4
o,p'-DDD (mitotane) treatment of canine pituitary-dependent hyperadrenocorticism.
J Am Vet Med Assoc. 1983 Mar 1;182(5):527-8.
5
Hypoadrenocorticism following therapy with o,p-DDD for hyperadrenocorticism in four dogs.
J Am Vet Med Assoc. 1982 Mar 15;180(6):638-41.
6
o,p-DDD in the treatment of Cushing's disease.
Vet Rec. 1978 May 27;102(21):470. doi: 10.1136/vr.102.21.470-a.
7
Medical treatment of pituitary-dependent hyperadrenocorticism in dogs.
Semin Vet Med Surg Small Anim. 1994 Aug;9(3):127-31.
8
The treatment of Cushing's disease in the dog.犬库欣氏病的治疗
Vet Rec. 1976 May 15;98(20):406. doi: 10.1136/vr.98.20.406.
9
Professional drug labeling.专业药品标签。
J Am Vet Med Assoc. 1993 May 15;202(10):1711-2;discussion 1713-7.
10
Prescribing cascade for non-food-producing species, and changes relating to Cushing's disease.非食用性物种的处方级联，以及与库欣病相关的变化。
Vet Rec. 2002 Nov 23;151(21):643.
Zotero 插件